xRead - Globus and Chronic Cough (April 2024)

Wamkpah et al.

Page 24

Author Manuscript Author Manuscript Author Manuscript Author Manuscript # Patients enrolled; completed therapy (males/ females) Average age in years Comparator Treatment duration Primary outcome measure

Secondary outcome measure(s)

Laryngeal EMG

Videostroboscopy

Time (days) to maximal effect GerdQ

Capsaicin cough challenge

63 Opioid analgesic: tramadol 50 mg TID PRN None 2 weeks CSI LCQ None 2 weeks Degree of

Nighttime cough

frequency (coughs/hr) CQLQ

Cough severity VAS

Cough global rating of change

RSI

GFI

Modified LCQ

Number of patients

improving on cough severity score

gabapentin maximum 900 mg daily or carbamazepine 100 mg TID (if gabapentin intolerable) None 4 weeks Subjective improvement (yes or no) None 3 weeks Subjective cough reduction None 8 weeks Cough

symptom score

persistent cough

compared to baseline

60.1 NK-1 inhibitor: orvepitant 30 mg daily None 4 weeks Daytime cough frequency (coughs/hr)

Subjective

improvement (yes or no)

Retrospective case series 12; 10 (6/6) 58 Neuromodulator: pregabalin started at 75 mg BID, maximum 150 mg BID None 4 weeks Subjective rating of chief complaint Retrospective case series 51; 35 (10/41) 47 Neuromodulator: None 4 weeks Cough severity score

1 or more months

intervention (n patients)

Reflux regimen: PPI/ antihistamine and

lifestyle modifications (3)

12; 12 (8/4) 52 Tricyclic antidepressant: 16; 12 (9/7) 47.8 Neuromodulator + PPI: 16; 16 amitriptyline 10 mg qHS

53 Neuromodulator:

47 Inhaled corticosteroid: fluticasone 250 μg/ inhalation BID or

Tricyclic antidepressant:

amitriptyline 25 mg qHS, maximum up to 50 mg daily neuromodulator:

Experimental

intervention (n patients) 50–60 mg daily (9)

baclofen 20 mg TID +

omeprazole 20 mg BID

budesonide 400 ng/ inhalation BID

gabapentin or pregabalin, dose NR (if amitriptyline intolerable) (8)

gabapentin 300 mg daily, maximum 600 mg BID

E: 67.3

C: 54.3

20; 20

(8/12)

(6/10)

33; 33

(10/23)

13; 13

(2/11)

11; 11

(1/10)

number (year) Location Study design

Prospective

case series

Prospective

case series

Prospective

case series

Prospective

case series

Prospective

case series

Prospective

case series

Retrospective cohort

New York,

NY USA

Downers

Grove, IL, USA

China

New York,

NY USA

Anyang, Korea

Manchester,

England, UK

Jackson, MS, USA

Indianapolis, IN, USA

Leuven,

Belgium

Lee et al (2005)

Bastian et al (2006)

Xu et al (2013) Shanghai,

Dion et al (2017)

Hong et al (2019)

Smith et al (2020)

Norris et al (2010)

Halum et al (2009)

Van de

Author or

clinical trial

Kerkhove et al (2012)

Laryngoscope . Author manuscript; available in PMC 2022 January 01.